Home > Report on the risk assessment of 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended).

European Monitoring Centre for Drugs and Drug Addiction. (2022) Report on the risk assessment of 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended). Luxembourg: Publications Office of the European Union. Risk assessment 35. DOI: 10.2810/671114.

[img]
Preview
PDF (Report on the risk assessment of 3-CMC)
1MB

This publication presents the data and findings of the risk assessment on 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC), carried out by the extended Scientific Committee of the EMCDDA on 19 November 2021. On the basis of the Risk Assessment Report, on 18 March 2022, the Commission decided that 3-CMC should be included in the definition of 'drug', in the Annex to Framework Decision 2004/757/JHA.

[See also, EMCDDA release: European Commission adopts measures to control two harmful new drugs amidst health concerns and surge in supply]

Item Type
Report
Publication Type
Irish-related, International, Report
Drug Type
New psychoactive substance
Intervention Type
Harm reduction, Screening / Assessment
Source
Date
18 March 2022
Identification #
Risk assessment 35. DOI: 10.2810/671114
Pages
90 p.
Publisher
Publications Office of the European Union
Corporate Creators
European Monitoring Centre for Drugs and Drug Addiction
Place of Publication
Luxembourg
EndNote
Related (external) link

Repository Staff Only: item control page